Compared with intravascular ultrasound (IVUS), optical coherence tomography (OCT) has relative merits and demerits for detecting plaque characteristics. It remains unknown whether the IVUS and OCT evaluations of plaque progression/ regression are consistent. We sought to analyse the correlations between IVUS and OCT evaluations of plaques at single time points, and compare temporal changes in the IVUS and OCT data.
Introduction
Coronary heart disease (CHD) is the major cause of morbidity and mortality worldwide, and therefore, optimal pharmacological interventions for slowing the progression or inducing the regression of coronary atheromas have been extensively studied during past decade. 1 -4 Intravascular ultrasound (IVUS), a sensitive intravascular imaging tool for the direct visualization of lumen morphology, has been widely used as a reference method for the assessment of coronary artery plaque progression in the above-mentioned studies. Although atheroma volume on IVUS is used as a standard surrogate for clinical end points, IVUS has a relatively low reproducibility in case of obstruction or distortion of the lumen border, and its resolution limits the investigation of alterations in plaque components, 5, 6 which are considered more relevant to atheroma stabilization. Optical coherence tomography (OCT) is another intravascular imaging modality, which employs near-infrared light and provides a resolution 10 times higher than that obtained with IVUS. 7 Numerous studies have shown the ability of OCT to detect coronary plaque characteristics including fibrous cap thickness, thin-cap fibroatheroma (TCFA), and lumen dimensions with high reproducibility. 8, 9 Recently, a few investigators have begun to evaluate plaque progression or regression using OCT due to its excellent histological correlations. 10, 11 However, to date, there are no comparative data available regarding the relationships between plaque progression and regression as assessed by IVUS and OCT. We sought to analyse the correlations between the IVUS and OCT assessments of lipid-rich plaques at single points in time and to compare the change in the IVUS and OCT data over time.
Methods

Patient population
Between May 2010 and July 2013, consecutive CHD patients who underwent both IVUS and OCT examinations during the same procedure were enrolled in the study. The protocol specified enrolment of patients who had proven coronary artery disease and underwent a clinically indicated coronary angiography, which demonstrated at least one non-culprit/nontarget obstruction with .20% stenosis of the angiographic luminal diameter. OCT-derived lipid-rich plaques examination showed at least one lesion with lipid content for .908 among the coronary angiography identified non-culprit/non-target lesions. Patients were excluded when they had (i) chronic total occlusion; (ii) an extremely tortuous or calcified vessel; and (iii) left main disease. In total, the data of 78 patients were extracted from the cardiac imaging database of the second Affiliated Hospital of Harbin Medical University. From these patients, 70 had available IVUS and OCT assessments at the 12-month follow-up. Of the 70 patients who underwent repeat IVUS and OCT imaging, five patients were excluded for suboptimal OCT (n ¼ 3) or IVUS (n ¼ 2) image quality due to artefacts or unsuccessful pullbacks. Thus, finally, 65 patients were included. This study was approved by the ethics committee of the Second Affiliated Hospital of Harbin Medical University (Harbin, China). All patients provided written informed consent.
Acquisition of OCT and IVUS imaging
Patients were pre-treated with 300 mg aspirin, 300 mg clopidogrel, and 100 U/kg heparin before the index procedure if they were not on maintenance therapy. IVUS examinations were performed at baseline and follow-up with 40 MHz Atlantis Pro Catheter (Boston Scientific) after the intracoronary administration of 200 mg nitroglycerin. The IVUS catheter was inserted at least 40 mm from the coronary artery ostium through a 6F guiding catheter. The transducer was pulled back at a rate of 1 mm/s. After the IVUS procedure, OCT was performed with the M2/M3 system (St Jude Medical, Westford, MA, USA), as previously described. 12 In brief, an occlusion balloon catheter was advanced to the proximal site of the target lesion and inflated at 0.5-0.7 atm to remove blood from the field of view. Saline was infused into the coronary artery from the distal tip of the occlusion balloon catheter. The entire length of the lesion was imaged with an automatic pullback device at a rate of 3 mm/s. The IVUS and OCT images were recorded automatically.
OCT analysis
OCT analysis was performed with proprietary offline software (LightLab Imaging, Inc., Westford, MA, USA) by two independent reviewers. Lipid plaques defined as a poor signal region with a diffuse border were analysed in all three coronary arteries. Two separate plaques in the same vessel were identified if a ≥10-mm reference segment was found between them; if no such segment could be found, they were regarded as a single long lesion. Lipid-rich plaque was defined as a lipid plaque presenting lipid content for .908. Lesions in vessels with diameter of .4 mm were excluded due to the shallow axial penetration of OCT. Corresponding IVUS and OCT images were identified by distances from landmarks such as side branches and stent edges. When there was a disagreement between the two investigators, a consensus was obtained. Lipid core arcs were measured every 1-mm interval throughout the lipid-rich plaque. The mean and maximum lipid core arcs were recorded. Lipid core length defined as the length of plaque with .908 lipid core arc was measured on the longitudinal view. The lipid index was computed by multiplying the mean lipid core arc by the lipid core length. 13 Fibrous cap thickness of lipid-rich plaque was measured thrice at the thinnest part, and then, the values were averaged. TCFA was defined as a lipid-rich plaque with a ,65-mm thin fibrous cap. 14 
IVUS analysis
The baseline and follow-up IVUS images of lipid-rich plaques, as determined using OCT, were independently analysed by two experienced investigators using semi-automatic software (EchoPlaque, Indec Systems, Mountain view, CA, USA). Side branches, calcifications, and/or stents were used as fiducial markers to allow frame-by-frame comparisons for matching the baseline and follow-up images. The observers traced the lumen and external elastic membrane (EEM) borders on one of every 30 digitized cross-sections to ensure a series of analysed slices spaced exactly 0.5 mm apart. Quantitative measurements included EEM and lumen cross-sectional area (CSA). Lumen and vessel volumes were computed for the entire length of the lesions by multiplying the EEM and lumen CSA by the distances between the neighbouring frames and then adding all corresponding products. Total atheroma volume (TAV) was calculated as the sum of the differences between the EEM and lumen areas in all evaluable cross-sections: TAV ¼ S(EEM CSA 2 LUMEN CSA). Percent atheroma volume (PAV) was calculated as the percentage of the sum of the EEM areas occupied by the TAV: PAV ¼ S(EEM CSA 2 LUMEN CSA)/SEEM CSA × 100. Substantial plaque progression and regression were defined as a .5% relative increase or decrease in PAV, respectively.
15,16
Statistical analysis
Statistical analysis was performed using SPSS version 17.0 and SAS version 9.1.3. Categorical variables were expressed as frequencies (percentages) and compared using the x 2 test or Fisher exact test. Continuous data were tested for normal distribution with the non-parametric one-sample Kolmogorov-Smirnov test and were presented as mean + SD if normally distributed. The differences in the laboratory results at baseline and follow-up were assessed using the paired t-test.
The relationships between OCT indices and IVUS results were evaluated with Pearson correlation coefficients. OCT measures at the baseline, at follow-up, and the changes from the baseline were compared among plaques showing progression, no change, and regression on IVUS by using repeated-measures analysis of variance (ANOVA). Fibrous cap thickness between baseline and follow-up in groups was also compared using repeated-measures ANOVA. The interaction between group and time (baseline/follow-up) represented the difference in the changes in OCT parameters over time among the three plaque groups. A P-value ,0.05 was considered to be statistically significant.
Results
The baseline characteristics of the patients are listed in Table 1 . All included patients received statin therapy. Among them, 44 patients (68%) received atorvastatin and 21 patients (32%) received rosuvastatin. Table 2 summarizes the laboratory results at baseline and follow-up. The mean low-density lipoprotein cholesterol (LDL-C) level at follow-up was 73.8 + 29.9 mg/dL, which represents a 33% reduction from the baseline (P , 0.001). A total of 88 lipid-rich plaques
Comparison of OCT and IVUS without any interventional therapy at the baseline were identified in 65 patients.
OCT versus IVUS results at single time points
The correlations between the IVUS and OCT data of the plaques at single time points are shown in Table 3 . At baseline, fibrous cap thickness was negatively correlated with TAV (r ¼ 20.28, P ¼ 0.009) but not with PAV (P ¼ 0.84). The maximum lipid core arc on OCT was significantly correlated with TAV (r ¼ 0.39, P , 0.001) and PAV (r ¼ 0.21, P ¼ 0.05). The lipid index on OCT was also significantly correlated with TAV (r ¼ 0.78, P , 0.001) and PAV (r ¼ 0.25, P ¼ 0.02). A similar pattern of correlations was observed at the 12-month follow-up, except that the correlation between fibrous cap thickness and TAV became relatively weak.
Changes on OCT versus changes on IVUS
The correlations between the changes in IVUS and OCT data from baseline to follow-up are presented in Table 4 . There were no significant correlations between the changes in OCT measures and the changes in IVUS results. Comparisons of OCT results among plaques showing substantial progression, substantial regression, and no substantial change on IVUS are listed in Table 5 . No significant difference in the temporal changes in fibrous cap thickness was observed among plaques showing progression, no change, and regression on IVUS (P ¼ 0.199). Fibrous cap thickness increased significantly in all three plaque groups (P , 0.0001). The changes in the maximum/mean lipid core arc and lipid index did not significantly differ among the three groups.
Plaque type
We identified 24 progressive plaques on IVUS, of which 17 were classified as TCFAs and 7 were classified as non-TCFAs on OCT at baseline. At the follow-up examination, 14 (82.35%) TCFAs had become non-TCFAs, and none of the 7 (100%) non-TCFAs had progressed to TCFAs. Among the 39 plaques without substantial changes on IVUS, 28 were TCFAs at the baseline, of which 22 (78.57%) changed into non-TCFAs at follow-up. Two (18.18%) of the other 11 non-TCFAs progressed to TCFAs during follow-up. The changes in plaque types in regressive plaques were very similar to the changes in progressive plaques. A schematic diagram of these changes is shown ( Figure 1) . Table 6 presents the frequency distribution of plaque types in the three groups. The correlations of fibrous cap thickness with lipid core arc and laboratory results and the correlations between their temporal changes are presented (see Supplementary material online, Table  S1 and S2). Change in fibrous cap thickness was negatively related with change in high sensitivity C reactive protein (r ¼ 20.22, P ¼ 0.037).
Discussion
The main findings of the present study can be summarized as follows: (i) the absolute volume (TAV) but not the relative volume (PAV) of plaques on IVUS negatively correlated with fibrous cap thickness on OCT at a given time point. (ii) There were no significant correlations between the changes in IVUS measurements and the changes in OCT results over time. (iii) The changes in fibrous cap thickness, lipid core arc, and lipid index on OCT did not differ among plaques showing substantial progression, substantial regression, and no substantial change on IVUS. (iv) No significant differences were found in the incidence of TCFAs among plaques with substantial progression, substantial regression, and no substantial change on IVUS at baseline and follow-up. Most TCFAs became non-TCFAs after standard drug treatment, regardless of the changes in plaque burden.
Although IVUS and OCT are the most useful invasive techniques for in vivo detecting of plaque characteristics, neither of them alone can provide an all-embracing assessment due to certain drawbacks. IVUS can show the artery wall and its layers, not merely the lumen, owing to its penetrating nature. This enables precise assessment of the vessel and lumen size and the plaque volume. 17 However, the low-resolution and speckled images on IVUS limit the study of microstructures and plaque composition. With the advantage of high resolution, OCT offers accurate measurement of fibrous cap thickness and has an exceptional ability to reveal plaque components including lipid pools. 8 Besides, OCT-derived TCFAs are widely considered to be vulnerable plaques. 18 However, very few authors have correlated the results of the two modalities. In this study, we observed that fibrous cap thickness was significantly and negatively correlated with TAV but not with PAV. This is probably because PAV takes into account the changes in vascular remodelling. Thus, our result demonstrates that plaques with larger absolute volumes have a thinner fibrous cap. This finding is consistent with a report by Miyamoto et al., 19 in which the plaque plus media CSA on IVUS were significantly larger in TCFAs than in non-TCFAs, as determined using OCT. However, the plaque burden was also larger in TCFAs in this report. This difference may be attributable to the relatively larger lipid arcs in TCFAs than in non-TCFAs. This hypothesis was confirmed in the present study, which showed that lipid burden correlates well with lipid core arc ( Table 3) . IVUS-derived atheroma volume has been widely used as a surrogate end point for clinical events in pharmacological intervention studies in recent years. 5 However, the role of IVUS in the evaluation of the progression/regression of coronary artery disease remains to be fully validated. There exist some discordance between the results of IVUS studies and trials with clinical end points using the same drugs. For instance, the antihypertensive drugs perindopril and amlodipine showed no difference in terms of the changes in atheroma volume in IVUS studies but caused a decrease in clinical events compared with placebo. 20, 21 Pioglitazone caused regression of atheroma volume but no changes in clinical events. Comparison of OCT and IVUS probably contributed to the discrepancy, IVUS itself might have a limitation in capturing the net effect of therapy on clinical outcomes. Several studies aiming to clarify the direct relationship between changes in atheroma volume and definite clinical events have yielded some controversy. 24, 25 It is important to note that the high dropout rate of patients with such clinical events in the study by Nicholls et al. 25 may have made their positive results unreliable.
Given the fact that acute coronary syndrome (ACS) is mainly caused by the rupture of vulnerable plaques rather than by progressive stenosis, it is promising to study whether changes in the surface features and/or components of plaques have more impact on clinical outcomes or whether concomitant intravascular imaging modalities are needed to achieve more appropriate surrogate measures.
To the best of our knowledge, the present study is the first to compare the changes in the OCT and IVUS data of OCT-derived lipid-rich plaques over time. We did not observe any significant correlations of changes in fibrous cap thickness with changes in PAV and TAV from baseline to follow-up. The changes in fibrous cap thickness did not differ among progressive, regressive, and unchanged plaques (classified by the change in PAV on IVUS). These data demonstrate that changes in surface characteristics could not be reflected by changes in plaque size or plaque burden. Fibrous cap thickness is a major determinant of plaque vulnerability. 26 A recent clinical study confirmed that the fibrous cap was thinner in ruptured plaques than in non-ruptured TCFAs, suggesting that plaques with thinner fibrous cap are more susceptible to rupture. 16 However, the study also found that large plaque burden and luminal narrowing on the occasion of plaque rupture resulted in ACS. This indicates that plaque burden and fibrous cap thickness are both critical factors associated with clinical events. Their combination may be superior to either factor alone in evaluating the changes of coronary artery plaques.
Another important finding of the present study is that there were no significant differences in the incidence of OCT-derived TCFAs among the three groups at baseline and follow-up. It is widely accepted that TCFAs are associated with coronary events. Some studies have confirmed that the prevalence of TCFA was higher in ACS patients than in patients with stable angina pectoris. recent study by Uemura et al. 29 showed that TCFAs on OCT were a potential predictor of subsequent angiographic progression. These studies indicate that TCFAs are an important morphological feature of vulnerable plaques. Our results demonstrate that changes in plaque type could not be distinguished using PAV on IVUS, suggesting that the clinical studies using atheroma volume as a primary end point might have missed some critical information. The present study also showed that changes in lipid core arc and lipid index had no significant correlations with changes in PAV and TAV and had no significant differences among the three plaque groups classified by IVUS. The lipid index is regarded as a surrogate marker of necrotic core burden. Our results demonstrate that changes in plaque size do not represent changes in lipid content. In addition, we found remarkable increases in fibrous cap thickness in all three groups, which indicated that fibrous cap thickness was more responsive to statin therapy than plaque size or plaque burden and that OCT may be a more sensitive tool than IVUS to evaluate plaque changes. Given the relatively limited effects of certain anti-atherosclerotic agents on plaque size on IVUS and the highly remarkable clinical benefits of these agents, the combination of OCT and IVUS may be a better choice to determine the changes of coronary plaques. However, data linking the changes on OCT and IVUS with clinical outcomes are needed to elucidate the clinical significance of the information offered by the combination of OCT and IVUS.
There are several limitations of this study. First, this was a retrospective study. Although consecutive patients who met the inclusion criteria were enrolled, selection bias was inevitable. Second, because of the shallow axial penetration of OCT, lesions in vessels with diameter of .4 mm were excluded in this study. Third, the definition of TCFAs on OCT is not totally consistent with the histological definition of TCFAs, which is attributable to the inability of OCT to measure the necrotic core size. Fourth, the sample size was relatively small, which may weaken the convincing power of our results. Fifth, the M2/M3 system precluded the evaluation of the most proximal parts of coronary arteries and was inferior in resolution and penetration depth compared with C7 system. Finally, all lesions were lipid-rich plaques; therefore, our results cannot be generalized to other types of plaques.
Conclusions
Although fibrous cap thickness on OCT was negatively correlated with plaque size on IVUS at single time points, changes in OCT parameters were not correlated with changes in IVUS measures over time. Disease progression and regression on IVUS is not associated with deterioration and improvement of the OCT parameters fibrous cap thickness, lipid core arc, lipid index, and TCFA. This indicates that the evaluations of lipid-rich plaque progression/regression by OCT and IVUS are not consistent. Data are presented as n (%). TCFA, thin-cap fibroatheroma.
